Militia Capital Management LLC Purchases Shares of 23,001 Moderna, Inc. $MRNA

Militia Capital Management LLC acquired a new position in Moderna, Inc. (NASDAQ:MRNA) during the first quarter, HoldingsChannel reports. The institutional investor acquired 23,001 shares of the company’s stock, valued at approximately $1,168,000.

Other hedge funds have also modified their holdings of the company. Capital World Investors bought a new position in shares of Moderna during the 4th quarter valued at approximately $378,299,000. Alyeska Investment Group L.P. bought a new stake in Moderna in the fourth quarter worth $95,209,000. Norges Bank bought a new stake in Moderna in the fourth quarter worth $79,707,000. Invesco Ltd. raised its stake in Moderna by 15.7% during the third quarter. Invesco Ltd. now owns 8,216,163 shares of the company’s stock valued at $212,223,000 after purchasing an additional 1,115,131 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in Moderna by 123.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,788,951 shares of the company’s stock valued at $52,775,000 after purchasing an additional 987,312 shares in the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Price Performance

NASDAQ MRNA opened at $54.82 on Monday. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. The company has a fifty day moving average of $59.37 and a two-hundred day moving average of $52.64. The firm has a market capitalization of $21.75 billion, a price-to-earnings ratio of -6.86 and a beta of 0.94. Moderna, Inc. has a 52 week low of $22.28 and a 52 week high of $85.60.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The business had revenue of $145.00 million for the quarter, compared to analysts’ expectations of $102.93 million. During the same quarter in the previous year, the business posted ($2.13) earnings per share. The business’s revenue was up 2.1% compared to the same quarter last year. On average, analysts predict that Moderna, Inc. will post -6.41 earnings per share for the current year.

Key Headlines Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna reported second-quarter EPS of -$1.97, better than the roughly -$2.03 consensus and an improvement from -$2.13 a year earlier. Revenue was approximately $145 million, while management reiterated its plan for up to 10% revenue growth in 2026. Moderna Reports Q2 Loss, Tops Revenue Estimates
• Positive Sentiment: The company improved its 2026 operating-expense outlook by about $200 million and now expects year-end cash of $4.7 billion to $5.2 billion, supporting its effort to reduce cash burn. Moderna also faces a potentially important catalyst on August 5, when regulators are scheduled to decide on its seasonal flu vaccine candidate, mFLUSIVA. Moderna Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Trading activity showed elevated interest in Moderna call options, with 82,913 contracts acquired versus a typical daily volume of 48,590. This may indicate speculative bullish positioning, but options activity alone does not establish a sustained change in investor sentiment.
• Negative Sentiment: Moderna’s Phase 3 mRNA-1403 norovirus vaccine trial did not meet the statistical criteria for early success at its interim analysis. The company plans to add another participant cohort, extending the trial into a fourth season and delaying clarity on a potential commercial opportunity. Moderna Adds New Cohort to Phase III Vaccine Trial
• Negative Sentiment: Investors remain concerned about Moderna’s dependence on declining COVID-19 vaccine sales. Although the quarterly loss narrowed, the company still posted a GAAP net loss of about $782 million, and reports characterized revenue as weaker than Wall Street expected. The norovirus setback therefore outweighed the earnings and cost-control improvements. Moderna Misses Quarterly Revenue Estimates on COVID Vaccine Weakness

Insider Buying and Selling

In related news, Director Noubar Afeyan sold 9,263 shares of the stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $46.84, for a total value of $433,878.92. Following the sale, the director directly owned 3,924 shares of the company’s stock, valued at $183,800.16. This represents a 70.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, President Stephen Hoge sold 53,336 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the completion of the sale, the president directly owned 1,483,848 shares of the company’s stock, valued at approximately $76,225,271.76. The trade was a 3.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 119,406 shares of company stock valued at $5,928,762. Company insiders own 10.80% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Royal Bank Of Canada increased their price objective on shares of Moderna from $38.00 to $45.00 and gave the company a “sector perform” rating in a research report on Tuesday, July 7th. Wolfe Research restated an “underperform” rating and issued a $25.00 target price on shares of Moderna in a report on Monday, July 20th. UBS Group restated a “neutral” rating on shares of Moderna in a research report on Tuesday, May 26th. Piper Sandler increased their price target on shares of Moderna from $69.00 to $77.00 and gave the company an “overweight” rating in a report on Friday, June 26th. Finally, Morgan Stanley lifted their price target on Moderna from $33.00 to $39.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 8th. Two analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and five have issued a Sell rating to the company’s stock. According to data from MarketBeat, Moderna presently has an average rating of “Reduce” and an average price target of $40.00.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.